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Abstract
Background: Serum β-trace protein (βTP, MW 23–29 kDa) is a marker of GFR impairment in renal patients. Recent
papers propose to predict residual renal function (RRF) in maintenance haemodialysis (MHD) patients from serum
concentrations of βTP and other small proteins, avoiding the collection of urine. Few data are available on the
removal of βTP in patients treated with dialysis membranes with different flux characteristics. The aim of this study
was to evaluate the effects of haemodialysis with low-flux, high-flux and super high-flux membranes on serum
concentrations of ßTP in MHD patients with null RRF.
Methods: Serum ßTP concentrations were measured before and after the first dialysis of the week in 51 MDH
patients treated by low-flux (n = 24), high-flux (n = 17), or super high-flux (n = 10) membranes. The removal of
β2-microglobulin (β2M, MW 11.8), cystatin C (Cys, MW 13.3), urea and creatinine was also analyzed.
Results: Low-flux membranes did not remove βTP, β2M and Cys whose concentration increased at the end of
dialysis. High-flux membrane removed more efficiently β2M and Cys than ßTP. Super high-flux membrane had
the highest efficiency to remove ßTP: mean reduction ratio (RR) 53.4%, similar to β2M (59.5%), and Cys (62.0%).
Conclusions: In conclusion, the plasma clearance of small proteins and particularly of βTP is dependent from
the permeability of the dialysis membranes Therefore, the reliability of the formulas proposed to predict RRF
from serum βTP and other LMWP may be affected by the different permeability of the dialysis membranes.
Keywords: β-trace protein, Low-molecular weight proteins, Maintenance haemodialysis, Permeability of dialysis
membranes, Residual renal function
Background
The measurement of residual renal function (RRF) is
clinically relevant in the management of maintenance
haemodialysis (MHD) patients, since RRF significantly
influences the adequacy of dialytic treatment and the
survival of MHD patients [1–3]. A careful monitoring
of RRF is particularly relevant when an incremental ap-
proach to the initiation of haemodialysis is used [4].
Frequently the evaluation of RRF is obtained from the
measurement of urinary clearance of creatinine and
urea, collecting the urine from the end of a dialysis to
the beginning of the next dialysis and measuring at the
same times the serum concentrations of creatinine and
urea [5, 6].
β-trace protein (βTP), also known as lipocalin-type pros-
taglandin D synthase, is a small protein (molecular weight
23–29 kDa, depending on the different glycosylation of
the molecule), isolated primarily from cerebrospinal
fluid [7–10]. Like other low-molecular weight proteins
(LMWPs), βTP is taken up by tubular cells and actively
degraded within their lysosomes [4]. Studies in chronic
kidney disease (CKD) patients demonstrated that serum
βTP is an adequate marker of glomerular filtration rate
(GFR) impairment with a diagnostic accuracy similar to
those of serum creatinine, cystatin C (Cys) and β2-
microglobulin (β2M) [11–15].
Quite recently the possibility to predict RRF in MHD
patients from serum concentration of βTP combined
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with β2M, or with β2M and Cys, has been addressed
[16, 17]. The need for studies comparing βTP clearance
with high-flux hemodialysis, superflux dialyzers, and
high-volume hemodiafiltration, has been highlighted
[18]. In fact, the different efficiency of membranes in the
removal of βTP from blood could affect the accuracy of
formulas proposed to calculate RRF in MHD patients
from serum βTP.
The aim of this study was to evaluate the effects of
haemodialysis with low-flux, high-flux and super high-
flux membranes on serum concentrations of ßTP in
MHD patients with null RRF.
Methods
We report the data on serum concentrations of ßTP in
51 MHD patients treated by low flux (n = 24), high-flux
(n = 17), and super high-flux (n = 10) membranes. The
removal from blood of β2M (MW 11.8), Cys (MW 13.3),
urea and creatinine was also analyzed for comparison.
These data, unpublished up to now, are from our data-
base of studies on the dialytic efficiency of haemodialysis
membranes. Patients were randomly allocated into the
different treatment groups.
Study design
Single center cross sectional study of prevalent MHD
patients. Setting: haemodialysis facility of the Nephrol-
ogy Division, Dept Medicine, University of Pisa.
Inclusion criteria: age >18 years; dialytic vintage
>6 months; residual diuresis null.
Exclusion criteria: incapacity to give informed consent.
Blood samples were drawn before starting and after
the end of the first haemodialysis of the week. To
minimize a post-dialysis rebound phenomenon, blood
samples were drawn 30 min after the end of dialysis.
Serum samples were stored into Eppendorf tubes at
−20 ° C up to biochemical determinations.
Ethics, consent and permissions
The Institutional Ethical Committee Azienda Ospedaliero-
Universitaria Pisana (2395/2007) approved the study on the
dialytic efficiency of haemodialysis membranes, that was
conducted according to Helsinki declarations. Patients gave
verbally their informed consent.
Dialyzers and membranes
Low-flux dialyzers: Polysulfone (F8, Fresenius, Bad
Homburg, Germany); Cellulose diacetate (Acepal 1700,
Diacepal 16, Hospal, Mirandola, Italy); High-flux dia-
lyzer: Acrylonitrile and sodium methallyl sulfonate co-
polymer (Nephral 500, Hospal Gambro, Mirandola,
Italy); Super high-flux dialyzer: Cellulose triacetate
(N190 FH, Nipro, Japan). Main characteristics of the
different dialyzers are reported in Table 1.
Laboratory methods
Urea was determined by an enzymatic method (UREA/
BUN Roche/Cobas; Roche Diagnostics, Mannheim,
Germany). Creatinine was measured with a rate-blanked
creatinine/Jaffé method (CREA Roche/Hitachi automated
analysis for Hitachi 917, Roche Diagnostics, Mannheim,
Germany). β2M was measured with an immune-enzymic
method (AxSym ß2-Microglobulin, Abbott, Wiesbaden,
Germany; mean reference value 0.99 ± 0.16 mg/L). Cys
was measured with a particle enhanced immune-
nephelometric method (N Latex Cystatin C, Siemens
Healthcare, Erlangen, Germany; reference intervals 0.53–
0.95 mg/L). βTP was measured with a particle enhanced
immune-nephelometric method (N Antiserum to human
βTP, Siemens Healthcare, Erlangen, Germany). Reference
intervals, calculated in our laboratory, were 0.37–0.77 mg/L
in men, and 0.40–0.70 mg/L in women [14].
Statistical analysis
Data are reported as means ± standard deviation. The
significances of the differences between groups were
assessed using non parametric Mann-Whitney test. Stat-
istical analysis was performed using MedCalc Statistical
Software version 16.4.3 (MedCalc Software, Ostend,
Belgium). A p value <0.05 was considered statistically
significant.
Results
Anthropometric and clinical data of patients are re-
ported in Table 2.
Few differences in dialytic prescription were found be-
tween the different groups of patients (Table 3).
Serum βTP, β2M and Cys decreased significantly after
the treatment with super high-flux and high-flux
Table 1 Main characteristics and properties of the different dialyzers, according to manufacturers data
Permeability Low-flux Low-flux High-flux Super high-flux
Dialysis Membrane Polysulfone Cellulose diacetate Acrylonitrile and sodium
methallyl sulfonate copolymer
Cellulose triacetate
KUF, mL/h/mmHg 7.5 13–13.7 65 84.7
Surface, m2 1.8 1.6–1.7 2.15 1.9
Urea clearance, mL/min 186 183–190 195 199
KUF = ultrafiltration coefficient; Standard conditions: QB = 200 mL/min; QD = 500 mL/min; TMP 100 mmHg; QUF = 0–10 ml/min
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membranes. On the contrary, serum βTP significantly
increased in patients treated with low-flux HD, due to
the dialytic dehydration. Serum βTP levels increased to
a similar extent after polysulfone or cellulose diacetate
treatment: +27 ± 23 and +21 ± 22%, respectively (p =
0.50). In patients treated by super high-flux membrane,
serum βTP was significantly lower, either before or
after dialytic treatment, than in those treated with high-
flux and low-flux membranes. The percent reduction
ratios of β2-microglobulin, cystatin C and β-trace pro-
tein increased progressively according to the flux of the
different membranes (Fig. 1).
In fact, low-flux membranes did not remove any
LMWP. High-flux membrane removed more efficiently
β2M (reduction ratio 62.0 ± 8.3%) and Cys (RR 73.2 ±
9.0%) than βTP (RR 26.3 ± 18.7%). Super high-flux mem-
brane removed efficiently all the three LMWPs with a
similar reduction ratio: β2M (RR 59.5 ± 16.2%), Cys
(62.0 ± 7.5%), and βTP (53.4 ± 15.5%). The removal of
Table 2 Anthropometric and clinical data of the 51 patients
Haemodialysis membrane Low-flux High-flux Super
High-flux
Number (males) 24 (12) 17 (16) 10 (9)
Age, years 65.7 ± 19.7 59.2 ± 11.7 64.6 ± 15.3
Dialysis Vintage, years 4.4 ± 3.2 6.9 ± 4.2x 2.7 ± 1.9**
Body weight, kg 64.0 ± 20.2 73.3 ± 13.3 76.9 ± 20.9
Body height, cm 163 ± 12 169 ± 8.6 171 ± 15.3
BMI, kg/m2 23.6 ± 5.2 25.7 ± 4.5 25.4 ± 3.9
Native kidney disease
Ischemic nephropathy 12 (50%) 2 (11.8%) 6 (60%)
Diabetic nephropathy 3 (12.5%) 2 (11.8%) 3 (30%)
Glomerulonephrites 3 (12.5%) 4 (23.5%) 1 (10%)
Interstitial nephrites 2 (8.3%) 4 (23.5%) 0
Chronic kidney disease 2 (8.3%) 3 (17.6%) 0
ADPKD and congenital
nephropathies
2 (8.3%) 2 (11.8%) 0
Mean values and standard deviations, or numbers and percentages are
reported. The statistical significance (p) of the differences between mean
values are indicated as follows: High-flux vs low-flux: x p < 0.05; Super high-flux
vs high-flux: ** p < 0.01
Table 3 Dialysis parameters and serum concentrations of urea,
creatinine, β-trace protein, β2-microglobulin and cystatin C
before (BD) and after (AD) haemodialysis
Low-Flux
n = 24
High-Flux
n = 17
Super High-Flux
n = 10
Mean ± SD Mean ± SD Mean ± SD
Dialysis length, h 3.7 ± 0.5 3.7 ± 0.3 4.2 ± 0.2** §§
Blood flow, mL/min 322 ± 40 368 ± 21x 330 ± 42
Dialysate flow, mL/min 500 500 500
Ultrafiltration, kg 2.8 ± 0.8 3.4 ± 0.9x 3.2 ± 1.0
Urea BD, mg/dL 145 ± 45 159 ± 40 122 ± 45
Urea AD, mg/dL 45 ± 20 48 ± 15 36 ± 18
Creatinine BD, mg/dL 9.5 ± 3.7 11.2 ± 1.9x 10.5 ± 3.5
Creatinine AD, mg/dL 3.7 ± 1.3 4.2 ± 0.9 3.9 ± 1.4
β-Trace protein BD,
mg/L
11.8 ± 4.8 10.9 ± 2.2 8.11 ± 2.4**§
β-Trace protein AD,
mg/L
14.8 ± 6.6 8.0 ± 2.5 3.8 ± 1.9***§§§
β2-Microglobulin BD,
mg/L
39.4 ± 15.3 24.4 ± 3.6xx 29.0 ± 12.0
β2-Microglobulin AD,
mg/L
42.9 ± 18.0 9.1 ± 1.4xxx*** 11.4 ± 5.1§§§
Cystatin C BD, mg/L 7.4 ± 1.9 9.36 ± 2.6xx 5.29 ± 0.9***§§
Cystatin C AD, mg/L 7.4 ± 2.4 2.4 ± 0.6xxx 1.9 ± 0.8§§§
Mean values and standard deviations (SD) are reported. The statistical
significance (p) of the differences between mean values are indicated as
follows: High-flux vs low-flux: x p < 0.05; xx p < 0.01; xxx p < 0.001; Super high-flux
vs low-flux: § p < 0.05; §§ p < 0.01; §§§ p < 0.001; Super high-flux vs high-flux:
** p < 0.01; *** p < 0.001
Fig. 1 Percent reduction ratios of β2-microglobulin, cystatin C and
β-trace protein in patients treated with dialyzers with different per-
meability: Low-flux, high-flux, and super high-flux. Percent reduction
ratios of urea and creatinine of the same patients are reported for
comparison. Mean values and 1 standard deviation from the mean
are drawn
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the small molecules urea and creatinine was very similar
with the different membranes, ranging 69.8–71.1% for
urea, and 61.0–62.9% for creatinine.
Discussion
In the setting of maintenance haemodialysis, a relation-
ship between RRF and serum LMWP concentration has
been indicated since long time [19, 20]. Different data
indicate a different removal of the various LMWP, deter-
mined by the dimensions of the molecules and by the
permeability characteristics of the dialysis membranes.
In particular, a significantly lower elimination for βTP
than Cys and β2M was found both in haemodiafiltration
(HDF) and haemofiltration (HF). βTP was only moder-
ately eliminated by HDF and not at all by HF, while
standard haemodialysis (HD) with low-flux membranes
did not remove any of the three LMWPs [21]. In the
same period, another study found that the removal of
βTP from the blood was modest and definitely lower
than that of β2M after HD and HDF with high-flux dia-
lyzers (KUf ranging 40–69 mL/h/mmHg) [22]. On the
contrary, serum levels of βTP were tightly associated to
residual diuresis of MHD patients suggesting that βTP
serum levels may serve as a surrogate marker for RRF
[20]. However, the possibility to evaluate RRF in dialysis
patients from serum concentrations of the LMWP cystatin
C has been addressed by different studies with conflicting
results [23, 24]. No data is available on the effect of dialy-
sis with super high-flux membranes on serum βTP levels.
Formulas based on serum levels of βTP and other
LMWP measured before the dialysis session have been
recently proposed to predict RRF in MHD patients
avoiding urine collection [16, 17]. Some differences can
be notices between the two studies. In particular, serum
βTP was unaffected by haemodialytic treatment [17],
while decreased after high-flux HD and even more after
HDF [16]. The editorial comment to these papers pro-
poses some caution notes due to the expected lower dia-
lyzer clearance of βTP, whose MW is higher than β2M
and Cys, and to the need for studies comparing βTP
clearance with high-flux haemodialysis, superflux dia-
lyzers, and high-volume haemodiafiltration [18].
Our previous results in CKD patients, not dialyzed,
demonstrated that βTP is an adequate marker of GFR
since its serum concentrations are determined exclu-
sively by GFR and age (multiple correlation coefficient
0.9245) [15].
The present study, which aims to evaluate the effects
of haemodialysis with low-flux, high-flux and super
high-flux membranes on serum concentrations of ßTP
in MHD patients with null RRF, was performed in re-
ports data from a small number of patients, which is a
limitation of the study. A strength of the study is the
very wide range of permeabilities of the dialytic
membranes from low- to super high-flux. No other data
are available on the effect of dialysis with super-high flux
membranes on serum levels of βTP in MHD patients.
The study was undertaken in different patients for the
different treatment strategies, which is another limitation
of the study. However, dialyzer blood flow, dialysate flow,
length and frequency of dialysis were similar in all patients,
and blood samples were drawn 30 min after the end of dia-
lysis to minimize eventual rebound phenomenon.
The results of this study demonstrate that the removal
of βTP from blood is null with low-flux dialysis mem-
branes, and progressively increases with the increase in
the permeability of the membranes. Haemodialysis with
super high-flux membrane has the highest efficiency in
decreasing serum levels of βTP. The differences among
βTP, β2M and Cys, observed during treatments with
low- and high-flux membranes, become insignificant
using a super high-flux membrane. Due to the different
removal efficiency, higher serum βTP were found, before
the first dialysis of the week, in patients treated with
low- and high-flux membranes than in those treated by
super high-flux membrane. These differences may have
an impact on the values of residual renal function calcu-
lated by means of the recently proposed formulas [16,
17]. We could not evaluate the relevance of this effect in
our patients, since they had no residual renal function.
Conclusions
The plasma clearance of small proteins and particularly
of βTP is dependent from the permeability of the dialysis
membranes. Super high-flux membrane have the highest
efficiency to remove ßTP from the blood. The differen-
tial elimination of small proteins in the different haemo-
dialysis techniques may affect the reliability of the
prediction of residual renal function from serum con-
centrations of small proteins.
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